Respected Editor,

Our team wants to draw attention to the clinical trial of the drug Plitidepsin for COVID-19 treatment. SARS-CoV-2 has caused a catastrophe worldwide devastatingly of over 208 million confirmed cases and more than 4.4 million deaths reported worldwide as of early September 2021 according to WHO. Despite of being the only approved antiviral drug for the specific treatment of COVID-19 i.e. Remdesivir, has limited efficacy against the virus [1]. Because of very limited options for treatment, scientists have to work hard to find out more treatment options to protect humanity from the next pandemic.

SARS-CoV-2 encounters many proteins for replicating inside the human cell, such proteins can be targeted for clinical trials for a new antiviral drug. One such host protein is Eukaryotic elongation factor-1A (eEF1A) and its inhibitor has come under significant interest for researchers [2]. The Plitidepsin’s antiviral activities are mediated through its inhibition of Eukaryotic Elongation Factor 1A (eEF1A) [3]. It has a cytostatic impact on cell proliferation and strongly inhibits nucleocapsid protein expression, thus inhibiting the cytoplasmic replication stage [4]. Plitidepsin isolated from the marine tunicate Aplidium Albicans (Fig. 1).

Plitidepsin has successfully completed a FDA phase II clinical trial for the treatment of COVID-19 by the pharmaceutical company PharmaMar and entered into a phase III with evidence of a safe clinical profile [5]. For the treatment of multiple myeloma Plitidepsin is also registered for Phase 1 clinical trial with bortezomib and dexamethasone [6]. As an antiviral, the company conducted a multicenter, randomized, parallel, open-label study to assess the safety profile, and clinical efficacy with three different Plitidepsin dose level cohorts (1.5mg - 2.0mg- 2.5mg), administered over three consecutive days, in patients with COVID-19, who required hospital admission. The patient’s viral load was evaluated quantitatively at the beginning of the treatment and on days 4th, 7th, 15th, and 30th. The study has demonstrated a substantial reduction of the viral load in patients between day 4th and 7th, the average reduction of the viral load on day 7th was 50% and on day 15th 70%. More than 90% of the patients included in the trial had medium or high viral loads at the start of therapy.

Scientists have screened the existing drugs approved in a various types of diseases, to assess how they restrain the SARS-CoV-2-persuaded in-vitro cytopathic effect and viral replication. Seventy two (72) likely antivirals that were previously suggested to impede infection of SARS-CoV-2, only 18% are working above the bar, including fenofibrate, camostat, nelfinavir mesylate hydrate, interferon 2-alpha, interferon-gamma, plitidepsin, novel cathepsin inhibitor and the well-known chloroquine derivatives and remdesivir. Among nanomolar efficacy category Plitidepsin was the only clinically approved drug [7].

We provided this knowledge because we want to draw the attention of researchers and the doctor communities that scientists and pharmaceutical companies are working very hard to discover new treatment regimens against SARS CoV 2. Moreover, the same development is also going from the platform of Terve Innova Company, which is in the primitive stages of trials on the adjunct treatment choices for the treatment of COVID-19. We should be

*Corresponding author: Shamail Zia, Department of Dermatology, Zia Medicare Skin Center, Karachi, Pakistan; Email: drshamailzia@gmail.com

Received: August 21, 2021; Revised: October 14, 2021; Accepted: October 23, 2021

DOI: https://doi.org/10.37184/lnjpc.2707-3521.3.25
proud of all of those people and companies working on these projects. Vaccines are available nowadays but still, a need for Anti-Viral drugs persists as evident from the history e.g. in 1918 (H1N1) viral pandemic, 1968 (H3N2) viral pandemic, and then 2019. We have to search for new options to prevent new pandemic waves [8]. It’s time to start investing more money in health care.

CONFLICT OF INTEREST
The authors declare no conflict of interest.

ACKNOWLEDGEMENTS
We are thankful for our mentors a) Dr. Naeem Uddin, practicing Dermatologist, Scientist and 5 USPTO Patents Holder Karachi, Pakistan, b) Dr. Atif Ali Hashmi, Department of Pathology Associate Professor Liaquat National Hospital Karachi, Pakistan, c) Dr. Adeel Ahmed, American Board Certified Dermatopathologist, Beckley, West Virginia, United States of America, and d) Dr. Ghassan Tranesh, Assistant Professor University of Arizona College of Medicine, Tucson, Arizona, United States of America, Fazail Zia, Muhammad Ali Khan, Vardah Zia, Syed Minhaj Hussain, Syed Rafay Yaqeen.

REFERENCES